Sarepta Therapeutics Inc
NASDAQ: SRPT
$126.07
-$1.03 (-0.8%)
Real Time Data Delayed 15 Min.
SRPT Articles
Sarepta Therapeutics received a favorable rating from Merrill Lynch, and as a result the stock soared in Tuesday's trading session.
Published:
Last Updated:
Thursday's top analyst upgrades, downgrades and initiations include Ally FInancial, Apple, Automatic Data Processing, Brocade Communications, Level 3 Communications and Tyco International.
Published:
Wednesday's leading analyst upgrades, downgrades and initiations from top research calls from around Wall Street include Exxon, Lowe's, Paycom Software, Under Armour, Wal-Mart and Verizon...
Published:
Monday may have started out as a fairly quiet news day for most stock sectors on a shortened week, but don't tell that to the Ebola drug stocks.
Published:
Some Ebola-related stocks had been heavily shorted as they were considered by many investors as the next would-be stock bubble from a major news event.
Published:
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Tuesday, October 28, 2014.
Published:
Sarepta Therapeutics shares took a big hit on Monday morning as disappointing news started its week out on the wrong foot.
Published:
ThinkstockJust when you thought the Ebola virus outbreak risk was dwindling down… Fresh headlines from Dow Jones and the New York post have put the markets on Ebola watch all over again. The...
Published:
Some of the Ebola high-flying stocks saw their share prices crater on Monday as Ebola fears are subsiding for several reasons.
Published:
Recently we have seen a surge in Ebola-related stocks across the board, but Friday trading brought a mixed view for this group.
Published:
Investors fan the flames of Ebola fears in the market, enabling these biotech companies to profit from these fears.
Published:
The sad news that Ebola patient Thomas Eric Duncan has died in a Dallas hospital now raises fears that Ebola drugs might not be a cure-all for patients.
Published:
Tekmira Pharmaceuticals downgrade also drags down Sarepta Therapeutics and BioCryst Pharmaceuticals.
Published:
With the CDC not releasing enough data on the patient, there could be an opportunity for traders on both sides of the Ebola story.
Published:
News has hit of the first confirmed Ebola case in the United States. Companies involved in potential drugs for Ebola have seen their shares pop.
Published: